These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
82 related articles for article (PubMed ID: 2864825)
21. Dose sparing strategy with intradermal influenza vaccination in patients with solid cancer. Jo YM; Song JY; Hwang IS; Lee J; Oh SC; Kim JS; Kim SR; Kim WJ; Cheong HJ J Med Virol; 2009 Apr; 81(4):722-7. PubMed ID: 19235853 [TBL] [Abstract][Full Text] [Related]
22. Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines. Hehme N; Engelmann H; Künzel W; Neumeier E; Sänger R Med Microbiol Immunol; 2002 Dec; 191(3-4):203-8. PubMed ID: 12458361 [TBL] [Abstract][Full Text] [Related]
23. [Evaluation of seroconversion after vaccination against influenza during the epidemic season 1991-1992 in Poland]. Brydak L; Rudnicka H Przegl Epidemiol; 1993; 47(3):275-83. PubMed ID: 8234846 [TBL] [Abstract][Full Text] [Related]
24. Serum and mucosal immunologic responses in children following the administration of a new inactivated intranasal anti-influenza vaccine. Greenbaum E; Furst A; Kiderman A; Stewart B; Levy R; Schlesinger M; Morag A; Zakay-Rones Z J Med Virol; 2001 Sep; 65(1):178-84. PubMed ID: 11505461 [TBL] [Abstract][Full Text] [Related]
25. Immune response after influenza vaccination in children with cancer. Matsuzaki A; Suminoe A; Koga Y; Kinukawa N; Kusuhara K; Hara T Pediatr Blood Cancer; 2005 Nov; 45(6):831-7. PubMed ID: 16007602 [TBL] [Abstract][Full Text] [Related]
26. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Oren S; Mandelboim M; Braun-Moscovici Y; Paran D; Ablin J; Litinsky I; Comaneshter D; Levartovsky D; Mendelson E; Azar R; Wigler I; Balbir-Gurman A; Caspi D; Elkayam O Ann Rheum Dis; 2008 Jul; 67(7):937-41. PubMed ID: 17981914 [TBL] [Abstract][Full Text] [Related]
27. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Van Damme P; Oosterhuis-Kafeja F; Van der Wielen M; Almagor Y; Sharon O; Levin Y Vaccine; 2009 Jan; 27(3):454-9. PubMed ID: 19022318 [TBL] [Abstract][Full Text] [Related]
28. [Influence vaccination: comparison of the effectiveness of two different vaccines]. Kuwert E; Thraenhart O; Werner J; Höher PG Med Klin; 1980 Oct; 75(21):755-8. PubMed ID: 7453623 [TBL] [Abstract][Full Text] [Related]
29. Clinical experience with inactivated, virosomal influenza vaccine. de Bruijn IA; Nauta J; Cramer WC; Gerez L; Palache AM Vaccine; 2005 Jul; 23 Suppl 1():S39-49. PubMed ID: 16005120 [TBL] [Abstract][Full Text] [Related]
30. Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture. Szymczakiewicz-Multanowska A; Groth N; Bugarini R; Lattanzi M; Casula D; Hilbert A; Tsai T; Podda A J Infect Dis; 2009 Sep; 200(6):841-8. PubMed ID: 19673651 [TBL] [Abstract][Full Text] [Related]
31. Immunogenicity and tolerability of inactivated flu vaccine in high risk and healthy children. Avila Aguero ML; Soriano-Fallas A; Umaña-Sauma MA; Ulloa-Gutierrez R; Arnoux S Medicina (B Aires); 2007; 67(4):351-9. PubMed ID: 17891930 [TBL] [Abstract][Full Text] [Related]
32. [Evaluation of the reactogenic and immunogenic properties of the influenza subunit polyvalent vaccine Grippovac SE-AZh during the immunization of schoolchildren]. Slepushkin AN; Obrosova-Serova NP; Feklisova LV; Bebisheva NI; Mel'nikova SK Vestn Akad Med Nauk SSSR; 1984; (1):75-9. PubMed ID: 6711101 [No Abstract] [Full Text] [Related]
33. Evaluation of immune responses to inactivated influenza vaccines prepared in embryonated chicken eggs and MDCK cells in a mouse model. Nerome K; Kumihashi H; Nerome R; Hiromoto Y; Yokota Y; Ueda R; Omoe K; Chiba M Dev Biol Stand; 1999; 98():53-63; discussion 73-4. PubMed ID: 10494959 [TBL] [Abstract][Full Text] [Related]
34. Reactogenicity to primary and repeated vaccination with influenza split virus vaccine. Hennessen W; Mauler R; Gruschkau H; Lehmann HG Dev Biol Stand; 1977 Jun 1-3; 39():289-93. PubMed ID: 604110 [TBL] [Abstract][Full Text] [Related]
35. Immunogenicity of trivalent subunit and split influenza vaccines (1989-90 winter season) in volunteers of different groups of age. Zei T; Neri M; Iorio AM Vaccine; 1991 Sep; 9(9):613-7. PubMed ID: 1950094 [TBL] [Abstract][Full Text] [Related]
36. Influenza virus antigens in human leukocytes after oral administration of live tissue culture influenza A monovaccine. Rukavishnikova GE; Alekseeva AK Acta Virol; 1977 Sep; 21(5):391-6. PubMed ID: 22233 [TBL] [Abstract][Full Text] [Related]
37. [Immunogenicity and the protective effectiveness of the subunit trivalent influenza vaccine Grippovac]. Chumakov MP; Malyshkina LP; Mart'ianova LI; Marinina VP; Mel'nikova SK Zh Mikrobiol Epidemiol Immunobiol; 1986 Feb; (2):44-9. PubMed ID: 2938372 [TBL] [Abstract][Full Text] [Related]
38. [Results of coded trials of the activity of the trivalent subunit influenza vaccine Grippovak in Moscow kindergartens in December 1983 through the 1st quarter of 1984]. Chumakov MP; Boĭko VM; Malyshkina LP; Mel'nikova SK; Rodin VI Vopr Virusol; 1987; 32(2):175-83. PubMed ID: 3300032 [TBL] [Abstract][Full Text] [Related]
39. Antibody response and persistence in volunteers following immunization with varying dosages of a trivalent surface antigen influenza virus vaccine. Jennings R; Smith TL; Mellersh AR; Clark A; Spencer RC; Potter CW J Hyg (Lond); 1985 Feb; 94(1):87-95. PubMed ID: 3973383 [TBL] [Abstract][Full Text] [Related]
40. [The evaluation of the reactogenicity, harmlessness and prophylactic efficacy of Grippol trivalent polymer-subunit influenza vaccine administered to schoolchildren]. El'shina GA; Gorbunov MA; Bektimirov TA; Lonskaia NI; Pavlova LI; Nikul'shin AA; Khaitov RM; Nekrasov AV; Ivanova AS; Matrosovich MN; Puchkova NG Zh Mikrobiol Epidemiol Immunobiol; 2000; (2):50-4. PubMed ID: 10808574 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]